In a move that signals the start of the acquisition cycle for the DOD’s largest purchased care contract, the Defense Health Agency (“DHA”) has released a draft RFP for the next generation of TRICARE Managed Care Support (“MCS”) contracts.  The TRICARE program, which provides health care services to nearly 10 million servicemembers and their families across the country, relies on private contractors to develop and maintain health care provider networks.  Given both the size of these contracts — the current third-generation MCS contracts are worth more than $53 billion — and their strategic importance to the DOD in delivering health care to millions of servicemembers, the TRICARE MCS procurement will be closely watched by both government and industry stakeholders alike.  And although elements of the program outlined in the draft RFP will be familiar to past participants in the MCS program, the next generation of MCS contracts also features several new characteristics that could significantly impact the contract award and performance.

TRICARE MCS contractors are responsible for administering and overseeing medical management, enrollment, claims processing, specialty care referrals, customer service, and data collection.  Due to the breadth of the program and the number of individuals it covers, responsibility for providing these services is divided and allocated on a regional basis.  Since 2002, the TRICARE program has been split into three geographic regions  — North, South, and West — with one MCS contractor responsible for providing services to each region.  Under the draft RFP, however, the North and South regions would be combined and renamed the “East” region.  Thus, the draft RFP contemplates only two awards: one each for the East and West regions.  This consolidation is likely to further intensify competition for what were already highly sought-after contracts.  In the previous procurement cycle, the three contract awards spawned six separate bid protests; now, with three incumbents (and probably numerous other challengers) vying for just two contracts, competition will be even more fierce.

Another significant change to the fourth generation of TRICARE MCS contracts involves the timeline for the procurement.  The third-generation TRICARE MCS contracts were originally scheduled to expire in 2015, but that date was pushed back due to extensive procurement delays associated with bid protests in each of the regions.  Consequently, it appears that the five-year performance periods for the MCS contracts are scheduled to run through 2015 in the North region, 2017 in the South region, and  2018 in the West region.  However, the recently released draft RFP contemplates an initial base period of performance beginning sometime in 2016, to be followed by five one-year option periods.[1]  This anticipated timeframe is notable for two reasons.  First, for a contract with a contemplated 2016 award date, it is early to be issuing a draft RFP.  This advance planning appears to be an attempt by DHA to avoid the delays in the start of performance that plagued the third-generation MCS contracts.[2]  Second, and perhaps more importantly, it is difficult to see how the government can begin performance with a new contractor before the current contracts expire — the government likely will have to terminate for convenience the MCS contracts in the South and West regions, which, according to GAO, are scheduled to run through 2017 and 2018, respectively. Doing so would have the advantage of aligning the performance start dates for TRICARE MCS contracts going forward, but it would significantly reduce the performance period for the current MCS contractors in the South and West regions.  The government possesses broad rights to terminate for convenience, but the regulations governing the settlement of terminations for convenience are complex.  Current MCS contract holders would be well-advised to consider taking advance steps to ensure that they are fairly compensated for work done and the preparations are made with regard to the potentially terminated portions of the contract, including a reasonable allowance for profit.

A final aspect of the RFP worthy of attention is a one-sentence declaration, buried in Section L.5.2.1, that states: “Please note that network providers are not consideredsubcontractors of the prime contractor, and therefore healthcare services provided by networkproviders may not be counted in the subcontract plan.”  The statement that “network providers are not considered subcontractors of the prime contractor” is remarkable in that it directly contradicts a recent pronouncement from the Department of Labor’s Administrative Review Board (“ARB”) in a case addressing precisely this point.  In OFCCP v. Florida Hospital of Orlando, the ARB held that a network health care provider (Florida Hospital of Orlando) was a subcontractor to Humana Military Healthcare Service, the current TRICARE MCS contractor for the South region.  The case was closely watched and widely reported — the decision meant that the hospital and other network providers would be subject to costly federal affirmative action and record-keeping requirements — and in response to widespread concern about the impact of the decision, DOL instituted a five-year moratorium on enforcement actions against TRICARE network providers.[3]  The significant attention surrounding the ARB’s holding makes the draft RFP’s statement to the contrary all the more curious.  As a practical matter, prospective participants in the fourth-generation MCS program should understand that network providers may very well be considered federal subcontractors, notwithstanding the draft RFP’s statement to the contrary.

The DHA has invited industry stakeholders to submit comments and questions on the draft RFP by Monday, December 8, 2014.  Interested offerors should take advantage of this opportunity:  the acquisition cycle for the next generation of MCS contracts may be only just beginning, but the key considerations that will shape the procurement are already becoming apparent.

 


[1]           The draft RFP does not identify a specific date of award, but it states that the first option period, scheduled to begin on April 1, 2017, will be preceded by a base period of at least nine months to facilitate a transition.

[2]           Indeed, a recent GAO report found that one of the major “lessons learned” from the previous generation of TRICARE MCS contract awards was that “more time may be required for the acquisition process.”

[3]           The moratorium does not, however, alter the agency’s stance that such providers are federal subcontractors.  Moreover, the moratorium is set to expire in 2019, two years before the scheduled expiration of the fourth-generation MCS contracts in 2021.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Michael Wagner Michael Wagner

Mike Wagner represents companies and individuals in complex compliance and enforcement matters arising in the public procurement context. Combining deep regulatory expertise and extensive investigations experience, Mike helps government contractors navigate detailed procurement rules and achieve the efficient resolution of government investigations and…

Mike Wagner represents companies and individuals in complex compliance and enforcement matters arising in the public procurement context. Combining deep regulatory expertise and extensive investigations experience, Mike helps government contractors navigate detailed procurement rules and achieve the efficient resolution of government investigations and enforcement actions.

Mike regularly represents contractors in federal and state compliance and enforcement matters relating to a range of procurement laws and regulations. He has particular experience handling investigations and litigation brought under the civil False Claims Act, and he routinely counsels government contractors on mandatory and voluntary disclosure considerations under the FAR, DFARS, and related regulatory regimes. He also represents contractors in high-stakes suspension and debarment matters at the federal and state levels, and he has served as Co-Chair of the ABA Suspension & Debarment Committee and is principal editor of the American Bar Association’s Practitioner’s Guide to Suspension & Debarment (4th ed.) (2018).

Mike also has extensive experience representing companies pursuing and negotiating grants, cooperative agreements, and Other Transaction Authority agreements (OTAs). In this regard, he has particular familiarity with the semiconductor and clean energy industries, and he has devoted substantial time in recent years to advising clients on strategic considerations for pursuing opportunities under the CHIPS Act, Inflation Reduction Act, and Bipartisan Infrastructure Law.

In his counseling practice, Mike regularly advises government contractors and suppliers on best practices for managing the rapidly-evolving array of cybersecurity and supply chain security rules and requirements. In particular, he helps companies assess and navigate domestic preference and country-of-origin requirements under the Buy American Act (BAA), Trade Agreements Act (TAA), Berry Amendment, and DOD Specialty Metals regulation. He also assists clients in managing product and information security considerations related to overseas manufacture and development of Information and Communication Technologies & Services (ICTS).

Mike serves on Covington’s Hiring Committee and is Co-Chair of the firm’s Summer Associate Program. He is a frequent writer and speaker on issues relating to procurement fraud and contractor responsibility, and he has served as an adjunct professor at the George Washington University Law School.

Photo of Jennifer Plitsch Jennifer Plitsch

Jennifer Plitsch leads the firm’s Government Contracts Practice Group, where she works with clients on a broad range of issues arising from both defense and civilian contracts including contract proposal, performance, and compliance questions as well as litigation, transactional, and legislative issues.

She…

Jennifer Plitsch leads the firm’s Government Contracts Practice Group, where she works with clients on a broad range of issues arising from both defense and civilian contracts including contract proposal, performance, and compliance questions as well as litigation, transactional, and legislative issues.

She has particular expertise in advising clients on intellectual property and data rights issues under the Federal Acquisition Regulations (FAR) and obligations imposed by the Bayh-Dole Act, including march-in and substantial domestic manufacturing. Jen also has significant experience in negotiation and compliance under non-traditional government agreements including Other Transaction Authority agreements (OTAs), Cooperative Research and Development Agreements (CRADAs), Cooperative Agreements, Grants, and Small Business Innovation Research agreements.

For over 20 years, Jen’s practice has focused on advising clients in the pharmaceutical, biologics and medical device industry on all aspects of both commercial and non-commercial agreements with various government agencies including:

  • the Department of Veterans Affairs (VA);
  • the Department of Health and Human Services (HHS), including the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH), and the Centers for Disease Control (CDC);
  • the Department of Defense (DoD), including the Defense Threat Reduction Agency (DTRA), the Defense Advanced Research Projects Agency (DARPA), and the Joint Program Executive Office for Chemical Biological Defense (JPEO-CBRN); and
  • the U.S. Agency for International Development (USAID).

She regularly advises on the development, production, and supply to the government of vaccines and other medical countermeasures addressing threats such as COVID-19, Ebola, Zika, MERS-CoV, Smallpox, seasonal and pandemic influenza, tropical diseases, botulinum toxin, nerve agents, and radiation events. In addition, for commercial drugs, biologics, and medical devices, Jen advises on Federal Supply Schedule contracts, including the complex pricing requirements imposed on products under the Veterans Health Care Act, as well as on the obligations imposed by participation in the 340B Drug Pricing program.

Jen also has significant experience in domestic sourcing compliance under the Buy American Act (BAA) and the Trade Agreements Act (TAA), including regulatory analysis and comments, certifications, investigations, and disclosures (including under the Acetris decision and Biden Administration Executive Orders). She also advises on prevailing wage requirements, including those imposed through the Davis-Bacon Act and the Service Contract Labor Standards.